Personalized treatment for normal and high-risk patients using immunotherapy and transplant with Dr. Ivan Borrello, MD, PhD, Johns Hopkins image

Personalized treatment for normal and high-risk patients using immunotherapy and transplant with Dr. Ivan Borrello, MD, PhD, Johns Hopkins

Posted on: Apr 30, 2015
Play Episode
Also available on
play podcast in spotifySpotify play podcast in apple podcastsApple Podcasts play podcast in youtubeYoutube
Description

Dr. Ivan Borrello, MD, PhD of Johns Hopkins shares his work to create a patient-specific immunotherapy using enhanced T cells from the patient's own bone marrow, for truly personalized medicine. In a myeloma patient, the immune system is depressed and can no longer kill off cancerous cells. His work extracts T cells from the bone marrow in an individual patient, expands them a hundredfold outside of the body in the presence of the tumor cells, and then after an autologous transplant gives them back to the patient. When they are re-introduced, they target the hundreds of proteins that could be causing tumor growth for that patient, not just a single protein. This is the first time that T cells are being taken from the bone marrow instead of the blood in order to target the tumor cells more specifically.  He compares this type of immunotherapy with the CAR T cell therapies and notes that this approach does not have the side effects found with the CAR T cell use. The Myeloma Crowd Radio Show with Dr. Ivan Borrello, MD

Overview

Dr. Ivan Borrello, MD, PhD of Johns Hopkins shares his work to create a patient-specific immunotherapy using enhanced T cells from the patient's own bone marrow, for truly personalized medicine. In a myeloma patient, the immune system is depressed and can no longer kill off cancerous cells. His work extracts T cells from the bone marrow in an individual patient, expands them a hundredfold outside of the body in the presence of the tumor cells, and then after an autologous transplant gives them back to the patient. When they are re-introduced, they target the hundreds of proteins that could be causing tumor growth for that patient, not just a single protein. This is the first time that T cells are being taken from the bone marrow instead of the blood in order to target the tumor cells more specifically.  He compares this type of immunotherapy with the CAR T cell therapies and notes that this approach does not have the side effects found with the CAR T cell use. The Myeloma Crowd Radio Show with Dr. Ivan Borrello, MD

On this episode
Healthtree contact Ivan Borrello, MD

Ivan Borrello, MD

Ivan Borrello, MD, is associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics…

Ivan Borrello, MD, is associate professor of oncology at the Johns Hopkins University School of Medicine and director of the Cell Therapy and cGMP Biologics Core for the Johns Hopkins Kimmel Cancer Center. He is a member of the Hematologic Malignancies and Bone Marrow Translational Program. Dr. Borello’s clinical research interest is in developing immune based therapies for the treatment of multiple myeloma. HIs laboratory interests have focused on the development of a novel approach of adoptive T cell therapy utilizing marrow infiltrating lymphocyte (MILs) as a more tumor specific T cell approach. This has led to establishing the first adoptive T cell trials at Johns Hopkins, and he is currently exploring this approach in other diseases including non-hematologic malignancies. Dr. Borrello is also examining strategies for treating minimal residual disease (MRD) in myeloma with the combination of immune modulation and whole cell-based vaccines. Dr. Borello served a fellowship at the Johns Hopkins School of Medicine, completed his residency in internal medicine at the University of Chicago Pritzker School of Medicine, and earned his medical degree from the Medical College of Virginia.
Healthtree contact Jennifer Ahlstrom

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Transcript

Related Content